**Indication**
Multi-drug resistant Mycobacterium tuberculosis

**INN**
Amikacin

**Medicine type**
Chemical agent

**Antibiotic groups**
ACCESS

**List type**
Complementary

**Additional notes**
Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

**Formulations**
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

**EML status history**
First added in 1999 (TRS 895)
Changed in 2007 (TRS 950)
Changed in 2009 (TRS 958)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Wikipedia**
Amikacin

**DrugBank**
Amikacin

---

**Summary of evidence and Expert Committee recommendations**

The Committee recommended deletion from the EML and/or EMLc of various formulations and strengths of amikacin (injection: 100 mg/2 mL (as sulfate) in 2 mL vial), ethambutol (oral liquid: 25 mg/mL), ethionamide (tablet: 125 mg), isoniazid (oral liquid: 50 mg/5 mL), linezolid (powder for oral liquid: 100 mg/5 mL), p-aminosalicylic acid (granules: 4 g in sachet) and pyrazinamide (oral liquid: 30 mg/mL), noting that they are not optimal formulations and strengths for tuberculosis treatment.